Drugs - MedicineNews.net - Medical Updates

Search results for "Cystic fibrosis"

Symdeko to treat the underlying cause of cystic fibrosis in people ages 12 and older with certain mutations in the CFTR gene: FDA approved

The U.S. Food and Drug Administration ( FDA ) has approved Symdeko ( Tezacaftor / Ivacaftor and Ivacaftor ) for treating the underlying cause of cystic fibrosis in people ages 12 and older who have tw ... read article

Orkambi improves lung function and reduces pulmonary exacerbations in people with cystic fibrosis who have two copies of the F508del mutation

The New England Journal of Medicine ( NEJM ) has published data from the two phase 3 studies of Orkambi ( Lumacaftor / Ivacaftor ), an investigational medicine designed to treat the underlying cause o ... read article

Cystic fibrosis: effect of Dornase alfa on inflammation and lung function

Dornase alfa ( Pulmozyme ) has been shown to reduce markers of inflammation and neutrophil-associated metalloproteinases in cystic fibrosis, suggesting a potential benefit from use of this therapy ear ... read article

European Commission: approval for Kalydeco, the first medicine to treat the underlying cause of cystic fibrosis in people with G551D mutation

Vertex Pharmaceuticals has announced that the European Commission has approved Kalydeco ( Ivacaftor ) for patients with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutatio ... read article

Vitamin-D supplementation for cystic fibrosis: no evidence of benefit or harm

Cystic fibrosis is a genetic disorder with multiorgan effects. In a subgroup with pancreatic insufficiency malabsorption of the fat soluble vitamins ( A, D, E, K ) may occur. Vitamin D is involved in ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article

Castration-resistant prostate cancer: Cabozantinib linked to high rates of complete or partial bone scan resolution, pain relief, improvements in hemoglobin, and tumor regression

Exelixis has reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer ( CRPC ) treated with Cabozantinib ( XL184; Cometriq ) in an ongoing phase 2 ... read article